Skip to main content

Table 5 Treatment characteristics of respondents with Crohn's disease and Ulcerative colitis.

From: A national survey on the patterns of treatment of inflammatory bowel disease in Canada

Treatments CD n (%) UC n (%) 95% CI for difference (P value)
PO 5ASA 956 (54%) 672 (74%) -23.7 to -16.4 (<0.001)
Topical Steroids/5ASA 183 (10%) 391 (43%) -36.1 to -29.1 (<0.001)
PO Steroids 623 (35%) 259 (28%) 2.8 to 10.2 (0.001)
6 MP/Azathioprine 424 (24%) 109 (12%) 8.9 to 14.7 (<0.001)
IV Steroids 90 (5%) 41 (5%) -1.1 to 2.2 (0.571)
Infliximab 99 (6%) 7 (1%) 3.6 to 6.0 (<0.001)
  1. PO: Per os 5ASA: 5-Aminosalicylates 6MP: 6-Mercaptopurince IV: Intravenous